Royalty Pharma finances biopharmaceutical innovation by purchasing rights to future royalty payments from approved or developing medicines. Its portfolio receives cash flows based on sales of partner companies' pharmaceutical products. The business can also structure funding transactions with drug developers, exposing investors to a diversified collection of medicine-related revenue streams without owning manufacturing operations.
Royalty Pharma plc (RPRX) has a MarketKingdoms composite score of 74.9 (B+), an B-range rating. It ranks 58th of 1,866 covered companies, 3rd of 78 in Healthcare (sector average 64.4) and 1st of 12 in Biotechnology. Scores as of 2026-10-26.
Its strongest lenses are KPI momentum at 99 (Healthcare average 78) and Stock selection at 90 (Healthcare average 79). Even its lowest lenses, Expansion (growth) at 52 (sector average 50) and Price (valuation) at 60 (sector average 50), are above the sector average.
| Lens | Type | RPRX | Healthcare average | Biotechnology average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 77 | 81 | 77 | 44th |
| Stock selection | Research signal | 90 | 79 | 78 | 100th |
| KPI momentum | Research signal | 99 | 78 | 75 | 100th |
| Catalyst watch | Research signal | 74 | 74 | 74 | 42nd |
| Price (valuation) | Fundamental lens | 60 | 50 | 30 | 67th |
| Expansion (growth) | Fundamental lens | 52 | 50 | 64 | 65th |
| Quality (profitability) | Fundamental lens | 80 | 50 | 55 | 94th |
| Trend (momentum) | Fundamental lens | 79 | 50 | 48 | 91st |
The most recent call analysed was held on 2026-08-05 (fiscal 2026 Q2). MarketKingdoms checks what management promised on each call against what it later delivered.
The stock's valuation gap is -17.8%: its price is well below the path its market, sector and industry moves explain (strongly undervalued versus the model path). Factor sensitivity: market beta 0.46, sector beta 1.09, industry beta -0.01; the factor model explains 47% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| BeOne Medicines Ltd ADR (ONC) | 73.4 | B+ | -26.6% |
| Regeneron Pharmaceuticals Inc. (REGN) | 72.7 | B+ | +7.7% |
| Vertex Pharmaceuticals Incorporated (VRTX) | 68.1 | B | -7.5% |
| argenx SE ADR (ARGX) | 68.0 | B | -27.3% |
| Incyte Corporation (INCY) | 68.0 | B | -18.8% |
| Alnylam Pharmaceuticals Inc. (ALNY) | 61.4 | B- | -18.1% |
| Bio-Techne Corporation (TECH) | 60.4 | B- | -22.2% |
| Insmed Inc. (INSM) | 60.0 | B- | -48.5% |
Royalty Pharma plc financial statements · Healthcare sector ranking · Biotechnology industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.